Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma

被引:8
作者
Sanchez Hernandez, Alfredo [1 ]
Jose Juan, Oscar [2 ]
Vidal Martinez, Jose [3 ]
Blanco, Remei [4 ]
Macia, Sonia [5 ]
Esquerdo Galiana, Gaspar [6 ]
Aparisi Aparisi, Francisco [7 ]
Garde Noguera, Javier [8 ]
Catot, Silvia [9 ]
Losa Gaspa, Ferran [10 ]
Garcia-Pinon, Francisco [11 ]
机构
[1] Consorcio Hosp Prov Castellon, Serv Oncol Med, Castellon de La Plana 12003, Spain
[2] Hosp Univ & Politecn La Fe, Med Oncol Serv, Valencia, Spain
[3] Hosp Arnau Vilanova, Serv Anal Clin, Valencia 46015, Spain
[4] Hosp Mutua de Terrassa, Med Oncol Serv, Barcelona 08221, Spain
[5] Hosp Gen Elda, Med Oncol Serv, Alicante 03600, Spain
[6] Clin Benidorm, Med Oncol Serv, Alicante 03501, Spain
[7] Hosp Virgen de los Lirios, Med Oncol Serv, Alicante 03804, Spain
[8] Hosp Arnau Vilanova, Med Oncol Serv, Valencia 46015, Spain
[9] Clin Althaia de Manresa, Med Oncol Serv, Barcelona 08243, Spain
[10] Hosp St Joan dEspi Moises Broggi, Med Oncol Serv, Barcelona 08970, Spain
[11] Hosp Prov Castellon, Fdn Comunidad Valenciana, Castellon de La Plana 12003, Spain
关键词
Circulating endothelial cell; NSCLC; Chemotherapy; PACLITAXEL-CARBOPLATIN; PERIPHERAL-BLOOD; SURROGATE MARKER; CLINICAL-VALUE; CANCER; ANGIOGENESIS; BEVACIZUMAB; PROGENITORS; CISPLATIN; SURVIVAL;
D O I
10.1007/s12094-014-1223-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Circulating endothelial cells (CEC) play an important role in tumor neovascularization and may have prognostic value in cancer patients. This study was designed to investigate the role of CEC as a marker for predicting platinum plus pemetrexed first-line chemotherapy efficacy in advanced non-squamous non-small cell lung cancer (NSCLC). A prospective study was performed whose main objective was to study whether the numbers of CEC at baseline and prior to the second and third cycle of chemotherapy were response predictors. Sixty-nine patients received cisplatin plus pemetrexed, and peripheral blood samples were performed at baseline and after second and third cycle. Separation and CEC count were performed using inmunomagnetic separation (CellSearch). The CEC count in 4 mL of peripheral blood was obtained prior to the first, second, and third cycle of treatment. Baseline levels and evolution of CEC were correlated with response to treatment according to RECIST criteria after three cycles of treatment. Sixty-nine patients were included: 43 (64.2 %) received cisplatin/pemetrexed and 24 (35.8 %) carboplatin/pemetrexed. Range of baseline CEC: 8-965 (mean of 153 cel/4 mL). The results after 3 cycles were: 25 partial responses (36.2 %), 17 cases of stabilization of disease (24.6 %), 16 of progressive disease (23.2 %) and 11 non-evaluables (16 %). No significant relationship between the baseline CEC count and response was found (p value = 0.831). Increase > 50 % between the first and second cycle was correlated significantly with progression disease (p = 0.008). Patients who had a baseline CEC count greater than the mean (> 153 cells/4 mL) showed longer progression-free survival and global survival without statistical significance. In this homogeneous group of patients with NSCLC, there is no correlation between response to treatment and CEC baseline levels. The increase in CEC numbers after the first cycle could be a negative predictive factor.
引用
收藏
页码:281 / 288
页数:8
相关论文
共 40 条
[1]   Biomarkers with Predictive and Prognostic Function in Non-Small Cell Lung Cancer: Ready for Prime Time? [J].
Aggarwal, Charu ;
Somaiah, Neeta ;
Simon, George R. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (07) :822-832
[2]  
[Anonymous], 2020, CA Cancer J Clin, DOI DOI 10.3322/CAAC.21590
[3]   American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer [J].
Azzoli, Christopher G. ;
Baker, Sherman, Jr. ;
Temin, Sarah ;
Pao, William ;
Aliff, Timothy ;
Brahmer, Julie ;
Johnson, David H. ;
Laskin, Janessa L. ;
Masters, Gregory ;
Milton, Daniel ;
Nordquist, Luke ;
Pfister, David G. ;
Piantadosi, Steven ;
Schiller, Joan H. ;
Smith, Reily ;
Smith, Thomas J. ;
Strawn, John R. ;
Trent, David ;
Giaccone, Giuseppe .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6251-6266
[4]   Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis [J].
Baggstrom, Maria Q. ;
Stinchcombe, Thomas E. ;
Fried, Daniel B. ;
Poole, Charles ;
Hensing, Thomas A. ;
Socinski, Mark A. .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (09) :845-853
[5]   Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity [J].
Beaudry, P ;
Force, J ;
Naumov, GN ;
Wang, A ;
Baker, CH ;
Ryan, A ;
Soker, S ;
Johnson, BE ;
Folkman, J ;
Heymach, JV .
CLINICAL CANCER RESEARCH, 2005, 11 (09) :3514-3522
[6]   Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients [J].
Beerepoot, LV ;
Mehra, N ;
Vermaat, JSP ;
Zonnenberg, BA ;
Gebbink, MFGB ;
Voest, EE .
ANNALS OF ONCOLOGY, 2004, 15 (01) :139-145
[7]   Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy [J].
Bidard, F. -C. ;
Mathiot, C. ;
Degeorges, A. ;
Etienne-Grimaldi, M. -C. ;
Delva, R. ;
Pivot, X. ;
Veyret, C. ;
Bergougnoux, L. ;
de Cremoux, P. ;
Milano, G. ;
Pierga, J. -Y. .
ANNALS OF ONCOLOGY, 2010, 21 (09) :1765-1771
[8]   Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Endostatin and Paclitaxel-Carboplatin Chemotherapy? A Retrospective Study [J].
Chu, Tian-Qing ;
Ding, Hao ;
Garfield, David H. ;
Gu, Ai-Qin ;
Pei, Jun ;
Du, Wei-Dong ;
Han, Bao-Hui .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (12) :1781-1789
[9]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[10]   Circulating Endothelial Cells and Microparticles as Prognostic Markers in Advanced Non-Small Cell Lung Cancer [J].
Fleitas, Tania ;
Martinez-Sales, Vicenta ;
Vila, Virtudes ;
Reganon, Edelmiro ;
Mesado, David ;
Martin, Maria ;
Gomez-Codina, Jose ;
Montalar, Joaquin ;
Reynes, Gaspar .
PLOS ONE, 2012, 7 (10)